Atrium Therapeutics, Inc. SEC filings RNA

Atrium Therapeutics, Inc. has 55 filings in SEC EDGAR's recent list, going back to Dec 10, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Atrium Therapeutics, Inc. SEC filings
Form Description Filed Period
8-K Current report
Regulation FD disclosure, Other events
Nov 2, 2026 Nov 2, 2026
8-K Current report
Other events
Oct 27, 2026 Oct 27, 2026
8-K/A Amended current report
Other events
Oct 9, 2026 Oct 7, 2026
8-K Current report
Material agreement, Unregistered share sale, Other events
Oct 8, 2026 Oct 7, 2026
10-Q Quarterly report Aug 13, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 13, 2026 Aug 13, 2026
8-K Current report
Other events
Jul 14, 2026 Jul 14, 2026
10-Q Quarterly report May 14, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 14, 2026 May 14, 2026
S-8 Employee stock plan registration Apr 17, 2026 —
8-K Current report
Material agreement, Change in control, Officer or director change
Feb 27, 2026 Feb 26, 2026
8-K Current report
Regulation FD disclosure
Feb 26, 2026 Feb 26, 2026
S-8 Employee stock plan registration Feb 26, 2026 —
SEC STAFF ACTION Filing Feb 26, 2026 —
CERT Filing Feb 26, 2026 —
10-12B/A Filing Feb 17, 2026 —
10-12B/A Filing Jan 30, 2026 —
10-12B Filing Dec 10, 2025 —

Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
RNA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
, Emerging growth company
SEC CIK
2093101

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.